This inventor holds 2 USPTO granted patents. Top assignee: Continental Pharma Incorporated. Active years: 1981.
Company Filing History:
Years Active: 1981
Title: The Innovations of Etienne T Hanon
Introduction
Etienne T Hanon is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of degenerative diseases. With a total of 2 patents to his name, Hanon's work focuses on innovative compositions that utilize natural compounds for therapeutic purposes.
Latest Patents
Hanon's latest patents include "Salts of (+)-catechine, their preparation and use" and "Pharmaceutical composition and therapeutical method for treating." The first patent describes a salt of (+)-catechin formed from the reaction of (+)-catechin with basic amino acids such as L-lysine and L-arginine. This invention also details the formation of a hydrosoluble double salt through the reaction of (+)-catechin with these amino acids and another inorganic or organic acid. The second patent outlines a pharmaceutical composition aimed at treating degenerative diseases of the articular cartilage, including osteoarthritis and chondromalacia. This composition contains (+)-catechin and/or its salts as active ingredients, which can be administered through various methods including orally, rectally, intra-articularly, intravenously, or topically.
Career Highlights
Hanon is currently associated with Continental Pharma Incorporated, where he continues to develop innovative pharmaceutical solutions. His work has been instrumental in advancing treatments for conditions that affect joint health and overall well-being.
Collaborations
Hanon has collaborated with notable colleagues such as Paul J Niebes and Daniel M Matagne, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Etienne T Hanon is a prominent figure in the field of pharmaceutical innovation, with a focus on utilizing natural compounds for therapeutic advancements. His patents reflect a commitment to improving treatment options for degenerative diseases, showcasing his dedication to enhancing patient care.